

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic⦠read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
$8.08
Price-4.04%
-$0.34
$1.395b
Small
127.2x
Premium
Premium
+14.9%
EBITDA Margin+0.8%
Net Profit Margin+24.3%
Free Cash Flow Margin+14.9%
EBITDA Margin+0.8%
Net Profit Margin+24.3%
Free Cash Flow Margin$314.853m
+31.1%
1y CAGR+34.5%
3y CAGR+56.5%
5y CAGR$12.008m
+71.5%
1y CAGR+39.2%
3y CAGR+35.1%
5y CAGR$0.07
+73.0%
1y CAGR+42.2%
3y CAGR+45.3%
5y CAGR$13.011m
$392.013m
Assets$379.002m
Liabilities$37.329m
Debt9.5%
1.4x
Debt to EBITDA$47.227m
+152.4%
1y CAGR+76.0%
3y CAGR+57.0%
5y CAGR